Intravenous bisphosphonate therapy does not acutely alter nuclear bone scan results Journal Article

Authors: Morris, P. G.; Van Poznak, C.; Modi, S.; Mak, A. F.; Patil, S.; Larson, S.; Hudis, C. A.; Divgi, C.; Grewal, R. K.
Article Title: Intravenous bisphosphonate therapy does not acutely alter nuclear bone scan results
Abstract: Introduction: Theoretically, the bisphosphonates used to treat metastatic bone disease could influence the results of nuclear bone scans which use the structurally similar technetium 99m methylene diphosphonate (99mTc MDP). A prospective clinical study was designed to explore this hypothesis. Patients and Methods: Patients with metastatic breast cancer receiving intravenous bisphosphonate (IVBP) therapy who had ≥3 osseous lesions on nuclear bone scan were eligible. A baseline bone scan (number 1) was performed as clinically indicated and IVBP with zoledronic acid was administered within 72 hours. A second bone scan (number 2) was performed within 72 hours of zoledronic acid dosing. Both bone scans were reviewed in a blinded fashion and assessed for changes in the number and intensity of osseous lesions. Ten patients were planned to yield at least 30 lesions. Results: Ten patients were enrolled. One patient withdrew consent and 1 was excluded due to protocol deviation. Among the 8 patients were 163 assessable osseous lesions. The median time from bone scan number 1 to IVBP was 1 day (range, 1-2 days). The median time from IVBP to bone scan number 2 was 2 days (range, 1-3 days). The paired imaging showed no changes in the total number of bone metastases. One hundred sixty-one lesions were identical in both scans; in 1 patient there were 2 lesions that were discordant, one more intense, the other less intense. Conclusion: These data do not support the hypothesis that IVBP therapy interferes with bone scan results.
Keywords: adult; clinical article; aged; bone neoplasms; middle aged; clinical trial; bone metastasis; technetium 99m; prospective study; radiopharmaceuticals; metastasis; breast cancer; image analysis; clinical assessment; drug structure; drug effect; breast neoplasms; bone lesion; drug uptake; tumor burden; medronate technetium tc 99m; infusions, intravenous; diphosphonates; intraductal carcinoma; bone density conservation agents; jaw diseases; osteonecrosis; radionuclide imaging; bone scintiscanning; zoledronic acid; imidazoles; bone metastases; bisphosphonate; bone scanning; methylene diphosphonate; jaw; technetium tc 99m medronate
Journal Title: Clinical Breast Cancer
Volume: 10
Issue: 1
ISSN: 1526-8209
Publisher: Elsevier Inc.  
Date Published: 2010-02-01
Start Page: 33
End Page: 39
Language: English
DOI: 10.3816/CBC.2010.n.004
PUBMED: 20133256
PROVIDER: scopus
Notes: --- - "Cited By (since 1996): 1" - "Export Date: 20 April 2011" - "CODEN: CBCLB" - "Source: Scopus"
Altmetric Score
MSK Authors
  1. Sujata Patil
    431 Patil
  2. Patrick Glyn Morris
    111 Morris
  3. Clifford Hudis
    887 Hudis
  4. Ravinder K Grewal
    63 Grewal
  5. Shanu Modi
    160 Modi
  6. Steven M Larson
    845 Larson